Novel highly sensitive NanoWire sensors for disease biomarker analysis
Nanowire-based platforms are expected to radically impact disease diagnosis and precision medicine thanks to their high surface-area-to-footprint ratio and optical waveguiding properties. The challenge is to cost-effectively produ...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BES-2014-068079
DISPOSITIVOS DE NANOHILOS DE SILICIO PARA LA DETECCION ULTRA...
88K€
Cerrado
TEC2015-72751-EXP
PLATAFORMA UNIVERSAL PARA LA DETECCION DE BIOMARCADORES BASA...
48K€
Cerrado
CTQ2011-24355
NUEVOS NANOMATERIALES POLIFUNCIONALIZADOS PARA LA CONSTRUCCI...
103K€
Cerrado
MAT2011-25870
NANOMATERIALES CON ALTA CAPACIDAD DE RECONOCIMIENTO MODULABL...
150K€
Cerrado
RYC-2016-20299
Nanotechnologies in biomedicine: point-of-care diagnostic sy...
309K€
Cerrado
MAT2013-44858-R
DISPOSITIVOS DE NANOHILOS DE SILICIO PARA LA DETECCION ULTRA...
178K€
Cerrado
Información proyecto NanoWi
Duración del proyecto: 23 meses
Fecha Inicio: 2022-10-06
Fecha Fin: 2024-09-30
Líder del proyecto
ALIGNEDBIO AB
No se ha especificado una descripción o un objeto social para esta compañía.
Presupuesto del proyecto
3M€
Descripción del proyecto
Nanowire-based platforms are expected to radically impact disease diagnosis and precision medicine thanks to their high surface-area-to-footprint ratio and optical waveguiding properties. The challenge is to cost-effectively produce nanowires in a reproducible manner. At Aligned Bio, we have developed a new technology that enables, for the first time, mass- and cost-effective production of nanowire sensors. Our solution relies on three core patented technologies, which when combined, allow to produce low-cost, high-quality nanowires with controlled diameters to reproducibly enhance waveguiding properties of nanowire platforms. This unique combination of novel technologies results in enhanced biomarker detection platform devices with 20 times higher sensitivity than current solutions in the market and, crucially, at low price.
To effectively carry out the tasks needed to reach TRL9, the EIC Accelerator project is crucial to bridging the critical risk-gap.